Brian Lian, Viking Therapeutics CEO

Viking soars on ear­ly-stage weight loss da­ta as it maps out PhII

Viking Ther­a­peu­tics will en­ter the next phase of the GLP-1 weight loss race, as the small biotech tout­ed ear­ly da­ta show­ing its in­ves­ti­ga­tion­al drug led …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.